Illumina Launches Infinium® HTS-24 Arrays
Complete the form below to unlock access to ALL audio articles.
Illumina, Inc. has launched an advanced high-throughput screening (HTS) array format that significantly increases the number of samples that can be processed on the Infinium® BeadChip family of genotyping arrays.
Illumina’s Infinium assay leverages proven chemistries on a new 24-sample HTS BeadChip that supports up to 750,000 markers per sample and increases scanning capacity by up to three-fold.
“We're excited to introduce this new array format as it enables our customers to perform larger, more powerful studies that enhance discovery,” said Christian Henry, Senior Vice President and General Manager, Genomic Solutions at Illumina.
Henry continued, “The 24-sample HTS BeadChip strengthens Illumina’s leading position in the array market and further demonstrates our ability to continue innovation on our array platform, providing customers with high-quality, high-throughput genotyping solutions. The new format allows us to offer breakthrough pricing per sample which is important to enable direct-to-consumer, biobanking, basic research, and agricultural applications.”
Illumina’s HumanOmniExpress BeadChip will be the first standard array available on the 24-sample HTS BeadChip, part of a portfolio of whole-genome genotyping arrays with new affordable pricing.
This powerful array contains approximately 700,000 markers including the latest updates from the 1,000 Genomes Project strategically selected to capture the greatest amount of common SNP variation and drive the discovery of novel associations with traits and disease.
It can also include up to 50,000 custom markers, making it ideal for those interested in large genotyping studies such as core labs, genome centers, and biobanks.
“We are very happy with the quality of data we obtained using the Illumina Infinium technologies,” said Mark Kelleher, Director of Laboratory Operations at 23andMe. “We are now very excited to deploy the higher-throughput BeadChips to enhance our ability to process larger volumes of samples as we expand our customer base.”
The first consortium-designed array on the 24-sample HTS BeadChip will leverage the new format and affordable pricing to help researchers explore the association between variants to five common cancers - breast, ovarian, colon, lung, and prostate.
The Infinium OncoArray-530K BeadChip (OncoArray), designed in collaboration with leading experts from the OncoArray consortium and enabled by the development of the 24-sample HTS BeadChip, delivers the core content found on Illumina’s Infinium HumanCore array along with approximately 250,000 additional candidate variants identified by OncoArray consortium members and room for 100,000 markers of semi-custom content.
The consortium members are planning a study of unprecedented size which will use the OncoArray to analyze over 425,000 samples and detect subtle associations within and between cancer types.
“The OncoArray is a major new tool for providing future insights into the relationship between genetic variants and cancer predisposition,” said Doug Easton, Professor of Genetic Epidemiology at Strangeways Research Laboratory, University of Cambridge, and a leader of the OncoArray consortium. “It was great working with Illumina to develop the OncoArray. The array contains the custom content we need, in a high-throughput format that will make our large-scale study feasible and should lead to a whole new wave of discoveries.”
The HumanOmniExpress BeadChip is now shipping in the 24-sample HTS format. The OncoArray, iSelect, HumanCoreExome, and HumanCore BeadChips in the 24-sample HTS format are expected to begin shipping in Q1 2014.
